Aclaris Therapeutics Inc. (ACRS) |
|
10.81 -0.06 (-0.55%)
|
01-16 05:36 |
|
Open: |
10.67 |
Pre. Close: |
10.87 |
|
High:
|
11.04 |
Low:
|
10.42 |
|
Volume:
|
451,275 |
Market Cap:
|
662M |
|
|
|
|
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel, small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company has a multi-stage portfolio of drug candidates powered by a research and development engine exploring protein kinase regulation. Its products pipeline includes ATI-450, an investigational oral, novel, small molecule selective MK2 inhibitor compound, which is being developed as a treatment for moderate to severe rheumatoid arthritis and additional immuno-inflammatory diseases; ATI-1777, an investigational topical soft JAK 1/3 inhibitor compound, which is being developed as a treatment for moderate to severe atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3 inhibitor compound, which is being developed as a treatment for psoriasis and/or inflammatory bowel disease. It also provides contract research services. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
11.052 - 11.142 |
11.142 - 11.203 |
|
Low:
|
10.239 - 10.335 |
10.335 - 10.4 |
|
Close:
|
10.681 - 10.834 |
10.834 - 10.936 |
|
Technical analysis |
as of: 2022-01-15 8:44:08 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 15.88  One year: 18.17 |
| Support: |
Support1: 10.42 Support2: 8.67 |
| Resistance: |
Resistance1: 13.60 Resistance2: 15.56 |
| Pivot: |
13.25 |
| Moving Average: |
MA(5): 11.62 MA(20): 13.61
MA(100): 15.40 MA(250): 18.56 |
| MACD: |
MACD(12,26): -0.73 Signal(9): -0.37 |
| Stochastic oscillator: |
%K(14,3): 7.39 %D(3): 13.61 |
| RSI: |
RSI(14): 27.92 |
| 52-week: |
High: 30.38 Low: 10.42 Change(%): -40.1 |
| Average Vol(K): |
3-Month: 41821 10-Days: 56989 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.ACRS has closed above bottom band by 6.8%. Bollinger Bands are 79.8% wider than normal. The large width of the bands suggest high volatility as compared to ACRS's normal range. The bands have been in this wide range for 2 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Fri, 14 Jan 2022
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Wed, 12 Jan 2022
Health Care Sector Update for 01/12/2022: ACRS,VCEL,NPCE,IRIX - Nasdaq
Wed, 12 Jan 2022
Healthcare Stocks Making Moves Wednesday: IMRN, VAXX, ERAS, MYNZ, NTRB, PHG, BBLG, ACRS - InvestorsObserver
Mon, 20 Dec 2021
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Buy" by Brokerages - MarketBeat
Fri, 03 Dec 2021
Aclaris Therapeutics Announces Publication of Preclinical Research of Zunsemetinib in Pancreatic Cancer in Science Translational Medicine - GlobeNewswire
Thu, 18 Nov 2021
Aclaris Therapeutics to Host Virtual R&D Day on December 7, 2021 - GlobeNewswire
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
 |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
|
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Neutral |
Debt to Equity: |
Neutral |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
61 |
| Shares Float (M) |
46 |
|
% Held by Insiders
|
4.14 |
|
% Held by Institutions
|
93.68 |
|
Shares Short (K)
|
2,050 |
|
Shares Short P. Month (K)
|
1,880 |
Stock Financials |
|
EPS
|
-1.550 |
|
EPS Est This Year
|
-3.100 |
|
EPS Est Next Year
|
-3.170 |
|
Book Value (p.s.)
|
3.540 |
|
Profit Margin
|
|
|
Operating Margin
|
-851.62 |
|
Return on Assets (ttm)
|
-21.7 |
|
Return on Equity (ttm)
|
-63.5 |
|
Qtrly Rev. Growth
|
14.5 |
|
Gross Profit (p.s.)
|
-0.457 |
|
Sales Per Share
|
0.112 |
|
EBITDA (p.s.)
|
-0.943 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-44 |
|
Levered Free Cash Flow (M)
|
-22 |
Stock Valuations |
|
PE Ratio
|
-6.97 |
|
PEG Ratio
|
|
|
Price to Book value
|
3.05 |
|
Price to Sales
|
96.77 |
|
Price to Cash Flow
|
-15.07 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
